secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001576885-25-000091
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026
--------------------------------------------------------------------------------

- Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.
- Net loss for Q2 2025 was $41.0M compared to $20.5M in Q2 2024, driven by higher R&D expenses.
- Topline results from Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's expected in late 2026.
- Announced collaboration with JCR Pharmaceuticals for Enhanced Brain Delivery therapy; non-clinical data expected early 2026.
- At AAIC 2025, presented data showing sabirnetug has 8,750-fold selectivity for toxic amyloid beta oligomers over monomers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/0001576885-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688525000091/abos-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001576885-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer